A Phase 3 interventional study of Docetaxel (XRP6976) and Oxaliplatin (SR96669) in Gastric Cancer, sponsored by Sanofi. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-13.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies testing docetaxel in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Docetaxel · Stomach Neoplasms.
Among the 103 studies testing docetaxel in Stomach Neoplasms, this one is the 4th largest by enrollment of the 99 interventional ones that give a count, is one of 3 that started in 2011, is one of 10 in phase 3, and was the 60th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →9 of the 103 studies testing docetaxel in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
Ukrainian Society of Clinical Oncology · Sites in Lithuania, Ukraine
Ages 18–80
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18–75
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 84 · Phase 3 13
First in 1997; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 530 is above the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 50 across the 99 interventional studies. Of the 68 that completed or were terminated, 21 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 103 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
15 studies in Stomach Neoplasms by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 14 finished, 4 (29%) have results posted.
Among the 15 studies in Stomach Neoplasms by Sanofi, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 3 in phase 3, and was the 10th registered.
Sanofi’s Stomach Neoplasms studies by the year they started, since 1998.
4 of the studies testing docetaxel in Stomach Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06028737Phase 3Ukrainian Society of Clinical OncologyTotal Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | 2027-04-25 |
| NCT07257575Guangdong Provincial People's HospitalA Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma | 2027-01-31 |
| NCT05184803Asan Medical CenterA Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer | 2027-06-30 |
| NCT07069712AstraZenecaA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | 2027-11-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 103 studies testing docetaxel in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 15 in Stomach Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
Participants in the neoadjuvant chemotherapy arm were treated for 3 cycles (1 cycle is 21 days) before surgery and treated for a year with S-1. Participants in the adjuvant chemotherapy arm underwent surgery and were treated for a year with S-1. All participants were followed during and after the study treatment until death or disease progression, whichever comes first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants underwent surgery within 2 weeks after randomization followed by adjuvant chemotherapy with S-1 \[(Gimeracil) + Oxo (Oteracil)\] 40 milligrams per square meter (mg/m\^2) administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after End-of-Treatment (EOT) until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 10 years).
Drug: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
Participants received neo-adjuvant chemotherapy with Docetaxel 50 mg/m\^2 intravenously (IV) for greater than or equal to (\>=)1 hour (hr) on Day 1 of each treatment cycle plus Oxaliplatin 100 mg/m\^2 IV for \>=2 hr on Day 1 of each treatment cycle plus S-1 \[(Gimeracil) + Oxo (Oteracil)\] 40 mg/m\^2 administered orally twice daily from Day 1 to 14, of each treatment cycle followed by surgery approximately 1-3 weeks after completion of neo-adjuvant chemotherapy and adjuvant chemotherapy with S-1 \[(Gimeracil) + Oxo (Oteracil)\] 40 mg/m\^2 administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after EOT until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 10 years).
Drug: Docetaxel (XRP6976) · Drug: Oxaliplatin (SR96669) · Drug: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
Pharmaceutical form:solution for infusion Route of administration: intravenous
Pharmaceutical form:solution for infusion Route of administration: intravenous
Drug page: Gimeracil
Pharmaceutical form:Tablet Route of administration: Oral
Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1
PFS was defined as the time from randomization to objective tumor progression, or recurrence or death. Progressive disease (PD) was defined as follows: 1) In Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) Arm, PD was determined according to the RECIST 1.1 Criteria during the neo-adjuvant chemotherapy period; 2) Irrespective of curative resection, if an intraoperative distant metastasis was observed or a distant metastasis was reported from pathology, it was considered PD; 3) If residual cancer cells were visually identified at the resection margin during surgery but could not be completely resected (R2), it was considered PD; 4) If residual cancer cells were finally confirmed at the resection margin during postoperative histology (R1), it was considered PD; 5) In case of finding a recurrence/distant metastasis or a new lesion during follow-up after R0 complete resection, it was defined as the first tumor assessment date when it was observed.
Time frame: 3 years
Overall Survival (OS)
OS was defined as the time from randomization to death due to any cause. Analyzed using Kaplan-Meier method.
Time frame: From randomization to date of death due to any cause (maximum duration: up to 10 years)
Number of Participants With Post-Operative Pathological Stage Response
TNM pathological stage was determined according to standardized histopathology and the American Joint Committee on Cancer (AJCC) staging system 7th Edition (Stages 0,IA,IB,IIA,IIB,IIIA,IIIB,IIIC and IV). Stage 0=carcinoma in situ with no metastatic potential; Stage IA=T1N0M0; Stage IB=T2N0M0,T1N1M0; Stage IIA=T3N0M0,T2N1M0,T1N2M0;Stage IIB=T4aN0M0,T3N1M0,T2N2M0,T1N3M0;Stage IIIA=T4aN1M0,T3N2M0,T2N3M0;Stage IIIB=T4bN0-1M0,T4aN2M0,T3N3M0;Stage IIIC=T4bN2-3M0, T4aN3M0 and Stage IV= distant metastases (M1) at diagnosis; where "T" denotes "tumor size" where T1: tumor invades lamina propria, muscularis mucosae, or submucosa; T2: invades muscularis propria; T3: invasion of subserosa; T4: T4a: penetrate serosa (visceral peritoneum) T4b: invade adjacent tissue and " N" denotes "nodes affected" where N1:1-2 positive lymph nodes; N2:3-6 positive lymph nodes; N3: 7 or more positive lymph nodes and "M" denotes metastases where M0: no distant metastases. Higher stages indicates worse outcome.
Time frame: Up to 10 years
Percentage of Participants With R0 Resection
Tumor condition was explained according to the Residual Tumor (R) Classification: R0; No residual cancer (negative cross-section), R1; Microscopically observed residual cancer (positive cross-section), R2; Macroscopically observed residual cancer.
Time frame: Up to 10 years
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
TEAEs were defined as adverse events (AE) that appeared or worsened during the treatment period (up to 30 days after the last dose of the investigational product). SAE was an AE or adverse drug reaction at any dose of the investigational product that corresponded to one of the following: resulting in death or is life threatening; requiring in-patient hospitalization or prolongation of existing hospitalization; resulting in persistent or significant disability of dysfunction; resulting in congenital anomaly or birth defect; important medical event.
Time frame: From randomization up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Number of Participants With Shift of Laboratory Parameters (Hematology) From Baseline Grade to Worst National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade >=3
NCI-CTCAE version 4.03 was used to determine Grade(Gr),where Gr refers to severity of AE:Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate;minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Hemoglobin(Hb)(Anemia) were based on Gr1:\<lower limit of normal (LLN)-10.0g/dL; Gr2:\<10.0-8.0g/dL; Gr3:\<8.0g/dL; Gr4:life-threatening consequences;Gr5:death. Hb increased:Gr 1:increase(incr.) in \>0-2g/dL above upper limit of normal(ULN);Gr2: incr. in \>2-4g/dL above ULN; Gr3:incr. in \>4gm/dL above ULN. White blood cell (WBC) decreased: Gr1:\<LLN - 3000/mm\^3;Gr2: \<3000-2000/mm\^3; Gr3:\<2000-1000/mm\^3;Gr4:\<1000/mm\^3. WBC (Leukocytosis):Gr3:\>100,000/mm\^3, Gr4:clinical manifestations of leucostasis;Gr5:Death. Abnormal Neutrophil count (ANC):- Gr1:\<LLN-1500/mm\^3;Gr2:\<1500-1000/mm\^3; Gr3: \<1000-500/mm\^3; Gr4:\<500/mm\^3. Platelet count decreased: Gr1:\<LLN-75,000/mm\^3;Gr2:\<75,000-50,000/mm\^3;Gr3:\<50,000-25,000/mm\^3;Gr4:\<25,000/mm\^3.
Time frame: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Number of Participants With Shift of Laboratory Parameters (Sodium and Potassium Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3
NCI-CTCAE version 4.03 was used to determine Gr,where Gr refers to severity of AE: Gr 1: mild; asymptomatic/mild symptoms; Gr 2: moderate; minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Sodium (Hyponatremia) were based on Gr1: \<LLN-130 mmol/L; Gr3: \<130-120 mmol/L; Gr4: \<120 mmol/L; life-threatening consequences; Gr5: death. Sodium (Hypernatremia):Gr 1: \>ULN-150 mmol/L; Gr2: \>150-155 mmol/L; Gr3:\>155-160 mmol/L;hospitalization; Gr4: \>160 mmol/L; life-threatening consequences; Gr5: Death. Potassium (Hypokalemia): Gr 1: \<LLN-3.0 mmol/L; Gr2: \<LLN-3.0 mmol/L; symptomatic; intervention indicated; Gr3: \<3.0-2.5 mmol/L; hospitalization indicated; Gr4: \<2.5 mmol/L; life-threatening consequences; Gr5: Death; Potassium(Hyperkalemia): Gr 1: \>ULN-5.5 mmol/L; Gr2: \>5.5-6.0 mmol/L; Gr3: \>6.0-7.0 mmol/L; hospitalization indicated; Gr4: \>7.0 mmol/L; life-threatening consequences; Gr5: Death.
Time frame: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Number of Participants With Shift of Laboratory Parameters (Calcium, Creatinine and Albumin Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3
NCI-CTCAE version 4.03 was used to determine Gr,where Gr refers to severity of AE:Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate;minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Calcium(Hypocalcemia) were based on Gr1: Corrected serum calcium of \<LLN-8.0 mg/dL; Gr2: Corrected serum calcium of \<8.0-7.0 mg/dL; Gr3: Corrected serum calcium of \<7.0-6.0 mg/dL ; Gr4: Corrected serum calcium of \<6.0 mg/dL;Gr5:death. Calcium(Hypercalcemia):Gr 1: Corrected serum calcium of \>ULN -11.5 mg/dL; Gr2: Corrected serum calcium of \>11.5-12.5 mg/dL; Gr3: Corrected serum calcium of \>12.5-13.5 mg/dL; Gr4: Corrected serum calcium of \>13.5 mg/dL;Gr5:Death. Creatinine increased: Gr 1: \>1-1.5\*baseline; \>ULN-1.5\*ULN; Gr2: \>1.5-3.0\*baseline; \>1.5-3.0\*ULN; Gr3: \>3.0 baseline; \>3.0-6.0\*ULN; Gr4: \>6.0 x ULN. Albumin(Hypoalbuminemia): Gr 1: \<LLN-3 g/dL; Gr2: \<3-2 g/dL; Gr3: \<2 g/dL; Gr4:life-threatening consequences;Gr5:Death.
Time frame: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Number of Participants With Shift of Laboratory Parameters (Aspartate Aminotransferase, Alanine Aminotransferase,Blood Bilirubin,Alkaline Phosphatase and Glucose Levels) From Baseline Grade to Worst NCI-CTCAE Grade >=3
NCI-CTCAE version 4.03 was used to determine Gr, where Gr refers to severity of AE: Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate; minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Aspartate and alanine aminotransferase increased were based on Gr1: \>ULN-3.0\*ULN; Gr2: \>3.0-5.0\*ULN; Gr3: \>5.0-20.0\*ULN; Gr4: \>20.0\*ULN. Blood bilirubin increased: Gr1: \>ULN-1.5\*ULN; Gr2 \>1.5-3.0\*ULN; Gr3: \>3.0-10.0\*ULN; Gr4: \>10.0\*ULN. Alkaline phosphatase increased: Gr1: \>ULN-2.5\*ULN; Gr2: \>2.5-5.0\*ULN; Gr3: \>5.0-20.0\*ULN; Gr4: \>20.0\*ULN. Glucose (Hypoglycemia): Gr 1: \<LLN-55 mg/dL; Gr2: \<55-40 mg/dL;Gr3: \<40-30 mg/dL; Gr4: \<30 mg/dL; Gr5:Death. Glucose (Hyperglycemia): Gr 1: Fasting glucose value \>ULN-160 mg/dL; Gr2: Fasting glucose value \>160-250 mg/dL; Gr3: \>250-500 mg/dL; Gr4: \>500 mg/dL; Gr5: Death.
Time frame: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)
Number of Participants With Shift of Laboratory Parameters (Creatinine Clearance [Chronic Kidney Disease]) From Baseline Grade to Worst NCI-CTCAE Grade >=3
NCI-CTCAE version 4.03 was used to determine Gr, where Gr refers to severity of AE: Gr 1: mild; asymptomatic/mild symptoms; Gr 2: moderate; minimal; Gr 3: severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Creatinine Clearance(Chronic kidney disease) were based on: Gr 1: estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) \<LLN-60ml/min/1.73 m\^2; Gr2: eGFR or CrCl 59-30 ml/min/1.73 m\^2; Gr3: eGFR or CrCl 29-15 ml/min/1.73 m\^2; Gr4: eGFR or CrCl \<15 ml/min/1.73 m\^2; Gr5: Death.
Time frame: From Baseline up to 30 days after last dose of study drug (maximum duration: up to 10 years)
The study was conducted at 18 sites in Korea. A total of 693 participants were screened between 30 December 2011 to 02 January 2019, of which, 163 were screen failures. Screen failures were mainly due to inclusion criteria not met.
| Milestone | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Started | 264 | 266 |
| Treated | 195 | 241 |
| Completed | 225 | 211 |
| Not completed | 39 | 55 |
| Withdrew: Withdrawal by subject | 32 | 41 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Other than specified above | 5 | 10 |
PFS was defined as the time from randomization to objective tumor progression, or recurrence or death. Progressive disease (PD) was defined as follows: 1) In Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) Arm, PD was determined according to the RECIST 1.1 Criteria during the neo-adjuvant chemotherapy period; 2) Irrespective of curative resection, if an intraoperative distant metastasis was observed or a distant metastasis was reported from pathology, it was considered PD; 3) If residual cancer cells were visually identified at the resection margin during surgery but could not be completely resected (R2), it was considered PD; 4) If residual cancer cells were finally confirmed at the resection margin during postoperative histology (R1), it was considered PD; 5) In case of finding a recurrence/distant metastasis or a new lesion during follow-up after R0 complete resection, it was defined as the first tumor assessment date when it was observed.
| percentage of participants | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 | 60.24 (53.55 to 66.28) | 66.82 (60.13 to 72.65) |
OS was defined as the time from randomization to death due to any cause. Analyzed using Kaplan-Meier method.
| months | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
TNM pathological stage was determined according to standardized histopathology and the American Joint Committee on Cancer (AJCC) staging system 7th Edition (Stages 0,IA,IB,IIA,IIB,IIIA,IIIB,IIIC and IV). Stage 0=carcinoma in situ with no metastatic potential; Stage IA=T1N0M0; Stage IB=T2N0M0,T1N1M0; Stage IIA=T3N0M0,T2N1M0,T1N2M0;Stage IIB=T4aN0M0,T3N1M0,T2N2M0,T1N3M0;Stage IIIA=T4aN1M0,T3N2M0,T2N3M0;Stage IIIB=T4bN0-1M0,T4aN2M0,T3N3M0;Stage IIIC=T4bN2-3M0, T4aN3M0 and Stage IV= distant metastases (M1) at diagnosis; where "T" denotes "tumor size" where T1: tumor invades lamina propria, muscularis mucosae, or submucosa; T2: invades muscularis propria; T3: invasion of subserosa; T4: T4a: penetrate serosa (visceral peritoneum) T4b: invade adjacent tissue and " N" denotes "nodes affected" where N1:1-2 positive lymph nodes; N2:3-6 positive lymph nodes; N3: 7 or more positive lymph nodes and "M" denotes metastases where M0: no distant metastases. Higher stages indicates worse outcome.
| Participants | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Stage 0 | 0 | 23 |
| Stage IA | 9 | 32 |
| Stage IB | 18 | 23 |
| Stage IIA | 30 | 47 |
| Stage IIB | 25 | 36 |
| Stage IIIA | 35 | 18 |
| Stage IIIB | 49 | 24 |
| Stage IIIC | 46 | 14 |
| Stage IV | 34 | 5 |
Tumor condition was explained according to the Residual Tumor (R) Classification: R0; No residual cancer (negative cross-section), R1; Microscopically observed residual cancer (positive cross-section), R2; Macroscopically observed residual cancer.
| percentage of participants | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Percentage of Participants With R0 Resection | 83.74 (79.13 to 88.35) | 95.50 (92.77 to 98.22) |
TEAEs were defined as adverse events (AE) that appeared or worsened during the treatment period (up to 30 days after the last dose of the investigational product). SAE was an AE or adverse drug reaction at any dose of the investigational product that corresponded to one of the following: resulting in death or is life threatening; requiring in-patient hospitalization or prolongation of existing hospitalization; resulting in persistent or significant disability of dysfunction; resulting in congenital anomaly or birth defect; important medical event.
| Participants | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Any TEAE | 190 | 237 |
| Any treatment emergent SAE | 57 | 102 |
| TEAEs leading to permanent discontinuation | 11 | 25 |
NCI-CTCAE version 4.03 was used to determine Grade(Gr),where Gr refers to severity of AE:Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate;minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Hemoglobin(Hb)(Anemia) were based on Gr1:\<lower limit of normal (LLN)-10.0g/dL; Gr2:\<10.0-8.0g/dL; Gr3:\<8.0g/dL; Gr4:life-threatening consequences;Gr5:death. Hb increased:Gr 1:increase(incr.) in \>0-2g/dL above upper limit of normal(ULN);Gr2: incr. in \>2-4g/dL above ULN; Gr3:incr. in \>4gm/dL above ULN. White blood cell (WBC) decreased: Gr1:\<LLN - 3000/mm\^3;Gr2: \<3000-2000/mm\^3; Gr3:\<2000-1000/mm\^3;Gr4:\<1000/mm\^3. WBC (Leukocytosis):Gr3:\>100,000/mm\^3, Gr4:clinical manifestations of leucostasis;Gr5:Death. Abnormal Neutrophil count (ANC):- Gr1:\<LLN-1500/mm\^3;Gr2:\<1500-1000/mm\^3; Gr3: \<1000-500/mm\^3; Gr4:\<500/mm\^3. Platelet count decreased: Gr1:\<LLN-75,000/mm\^3;Gr2:\<75,000-50,000/mm\^3;Gr3:\<50,000-25,000/mm\^3;Gr4:\<25,000/mm\^3.
| Participants | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Hb(Anemia) Gr 0 at Baseline to Gr >=3 | 0 | 0 |
| Hb(Anemia) Gr 1 at Baseline to Gr >=3 | 0 | 4 |
| Hb(Anemia) Gr 2 at Baseline to Gr >=3 | 1 | 1 |
| Hb(Anemia) Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Hb(Anemia) Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hb(Anemia) Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Hb increased Gr 0 at Baseline to Gr >=3 | 0 | 0 |
| Hb increased Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| Hb increased Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| Hb increased Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Hb increased Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hb increased Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| WBC decreased Gr 0 at Baseline to Gr >=3 | 1 | 8 |
| WBC decreased Gr 1 at Baseline to Gr >=3 | 0 | 1 |
| WBC decreased Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| WBC decreased Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| WBC decreased Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| WBC decreased Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| WBC (Leukocytosis) Gr 0 at Baseline to Gr >=3 | 0 | 1 |
| WBC (Leukocytosis) Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| WBC (Leukocytosis) Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| WBC (Leukocytosis) Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| WBC (Leukocytosis) Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| WBC (Leukocytosis) Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| ANC Gr 0 at Baseline to Gr >=3 | 14 | 40 |
| ANC Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| ANC Gr 2 at Baseline to Gr >=3 | 1 | 0 |
| ANC Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| ANC Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| ANC Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Platelet count decreased Gr0 at Baseline to Gr >=3 | 0 | 5 |
| Platelet count decreased Gr1 at Baseline to Gr >=3 | 0 | 0 |
| Platelet count decreased Gr2 at Baseline to Gr >=3 | 0 | 0 |
| Platelet count decreased Gr3 at Baseline to Gr >=3 | 0 | 0 |
| Platelet count decreased Gr4 at Baseline to Gr >=3 | 0 | 0 |
| Platelet count decreased Gr5 at Baseline to Gr >=3 | 0 | 0 |
NCI-CTCAE version 4.03 was used to determine Gr,where Gr refers to severity of AE: Gr 1: mild; asymptomatic/mild symptoms; Gr 2: moderate; minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Sodium (Hyponatremia) were based on Gr1: \<LLN-130 mmol/L; Gr3: \<130-120 mmol/L; Gr4: \<120 mmol/L; life-threatening consequences; Gr5: death. Sodium (Hypernatremia):Gr 1: \>ULN-150 mmol/L; Gr2: \>150-155 mmol/L; Gr3:\>155-160 mmol/L;hospitalization; Gr4: \>160 mmol/L; life-threatening consequences; Gr5: Death. Potassium (Hypokalemia): Gr 1: \<LLN-3.0 mmol/L; Gr2: \<LLN-3.0 mmol/L; symptomatic; intervention indicated; Gr3: \<3.0-2.5 mmol/L; hospitalization indicated; Gr4: \<2.5 mmol/L; life-threatening consequences; Gr5: Death; Potassium(Hyperkalemia): Gr 1: \>ULN-5.5 mmol/L; Gr2: \>5.5-6.0 mmol/L; Gr3: \>6.0-7.0 mmol/L; hospitalization indicated; Gr4: \>7.0 mmol/L; life-threatening consequences; Gr5: Death.
| Participants | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Hyponatremia Gr 0 at Baseline to Gr >=3 | 1 | 7 |
| Hyponatremia Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| Hyponatremia Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| Hyponatremia Gr 3 at Baseline to Gr >=3 | 0 | 1 |
| Hyponatremia Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hyponatremia Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Hypernatremia Gr 0 at Baseline to Gr >=3 | 0 | 0 |
| Hypernatremia Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| Hypernatremia Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| Hypernatremia Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Hypernatremia Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hypernatremia Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Hypokalemia Gr 0 at Baseline to Gr >=3 | 1 | 2 |
| Hypokalemia Gr 1 at Baseline to Gr >=3 | 1 | 1 |
| Hypokalemia Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| Hypokalemia Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Hypokalemia Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hypokalemia Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Hyperkalemia Gr 0 at Baseline to Gr >=3 | 1 | 4 |
| Hyperkalemia Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| Hyperkalemia Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| Hyperkalemia Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Hyperkalemia Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hyperkalemia Gr 5 at Baseline to Gr >=3 | 0 | 0 |
NCI-CTCAE version 4.03 was used to determine Gr,where Gr refers to severity of AE:Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate;minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Calcium(Hypocalcemia) were based on Gr1: Corrected serum calcium of \<LLN-8.0 mg/dL; Gr2: Corrected serum calcium of \<8.0-7.0 mg/dL; Gr3: Corrected serum calcium of \<7.0-6.0 mg/dL ; Gr4: Corrected serum calcium of \<6.0 mg/dL;Gr5:death. Calcium(Hypercalcemia):Gr 1: Corrected serum calcium of \>ULN -11.5 mg/dL; Gr2: Corrected serum calcium of \>11.5-12.5 mg/dL; Gr3: Corrected serum calcium of \>12.5-13.5 mg/dL; Gr4: Corrected serum calcium of \>13.5 mg/dL;Gr5:Death. Creatinine increased: Gr 1: \>1-1.5\*baseline; \>ULN-1.5\*ULN; Gr2: \>1.5-3.0\*baseline; \>1.5-3.0\*ULN; Gr3: \>3.0 baseline; \>3.0-6.0\*ULN; Gr4: \>6.0 x ULN. Albumin(Hypoalbuminemia): Gr 1: \<LLN-3 g/dL; Gr2: \<3-2 g/dL; Gr3: \<2 g/dL; Gr4:life-threatening consequences;Gr5:Death.
| Participants | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Hypocalcemia Gr 0 at Baseline to Gr >=3 | 1 | 0 |
| Hypocalcemia Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| Hypocalcemia Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| Hypocalcemia Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Hypocalcemia Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hypocalcemia Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Hypercalcemia Gr 0 at Baseline to Gr >=3 | 1 | 1 |
| Hypercalcemia Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| Hypercalcemia Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| Hypercalcemia Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Hypercalcemia Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hypercalcemia Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Creatinine increased Gr 0 at Baseline to Gr >=3 | 4 | 8 |
| Creatinine increased Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| Creatinine increased Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| Creatinine increased Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Creatinine increased Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Creatinine increased Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Hypoalbuminemia Gr 0 at Baseline to Gr >=3 | 1 | 2 |
| Hypoalbuminemia Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| Hypoalbuminemia Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| Hypoalbuminemia Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Hypoalbuminemia Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hypoalbuminemia Gr 5 at Baseline to Gr >=3 | 0 | 0 |
NCI-CTCAE version 4.03 was used to determine Gr, where Gr refers to severity of AE: Gr 1:mild; asymptomatic/mild symptoms; Gr 2:moderate; minimal; Gr 3:severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Aspartate and alanine aminotransferase increased were based on Gr1: \>ULN-3.0\*ULN; Gr2: \>3.0-5.0\*ULN; Gr3: \>5.0-20.0\*ULN; Gr4: \>20.0\*ULN. Blood bilirubin increased: Gr1: \>ULN-1.5\*ULN; Gr2 \>1.5-3.0\*ULN; Gr3: \>3.0-10.0\*ULN; Gr4: \>10.0\*ULN. Alkaline phosphatase increased: Gr1: \>ULN-2.5\*ULN; Gr2: \>2.5-5.0\*ULN; Gr3: \>5.0-20.0\*ULN; Gr4: \>20.0\*ULN. Glucose (Hypoglycemia): Gr 1: \<LLN-55 mg/dL; Gr2: \<55-40 mg/dL;Gr3: \<40-30 mg/dL; Gr4: \<30 mg/dL; Gr5:Death. Glucose (Hyperglycemia): Gr 1: Fasting glucose value \>ULN-160 mg/dL; Gr2: Fasting glucose value \>160-250 mg/dL; Gr3: \>250-500 mg/dL; Gr4: \>500 mg/dL; Gr5: Death.
| Participants | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Aspartate aminotransferase Gr0 at Baseline toGr>=3 | 1 | 1 |
| Aspartate aminotransferase Gr1 at Baseline toGr>=3 | 0 | 0 |
| Aspartate aminotransferase Gr2 at Baseline toGr>=3 | 0 | 0 |
| Aspartate aminotransferase Gr3 at Baseline toGr>=3 | 0 | 0 |
| Aspartate aminotransferase Gr4 at Baseline toGr>=3 | 0 | 0 |
| Aspartate aminotransferase Gr5 at Baseline toGr>=3 | 0 | 0 |
| Alanine aminotransferase Gr0 at Baseline to Gr >=3 | 0 | 1 |
| Alanine aminotransferase Gr1 at Baseline to Gr >=3 | 0 | 0 |
| Alanine aminotransferase Gr2 at Baseline to Gr >=3 | 0 | 0 |
| Alanine aminotransferase Gr3 at Baseline to Gr >=3 | 0 | 0 |
| Alanine aminotransferase Gr4 at Baseline to Gr >=3 | 0 | 0 |
| Alanine aminotransferase Gr5 at Baseline to Gr >=3 | 0 | 0 |
| Bilirubin increased Gr 0 at Baseline to Gr >=3 | 2 | 4 |
| Bilirubin increased Gr 1 at Baseline to Gr >=3 | 1 | 0 |
| Bilirubin increased Gr 2 at Baseline to Gr >=3 | 1 | 0 |
| Bilirubin increased Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Bilirubin increased Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Bilirubin increased Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Alkaline phosphatase Gr 0 at Baseline to Gr >=3 | 3 | 0 |
| Alkaline phosphatase Gr 1 at Baseline to Gr >=3 | 0 | 0 |
| Alkaline phosphatase Gr 2 at Baseline to Gr >=3 | 0 | 0 |
| Alkaline phosphatase Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Alkaline phosphatase Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Alkaline phosphatase Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Hypoglycemia Gr 0 at Baseline to Gr >=3 | 4 | 0 |
| Hypoglycemia Gr 1 at Baseline to Gr >=3 | 1 | 0 |
| Hypoglycemia Gr 2 at Baseline to Gr >=3 | 1 | 0 |
| Hypoglycemia Gr 3 at Baseline to Gr >=3 | 0 | 0 |
| Hypoglycemia Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hypoglycemia Gr 5 at Baseline to Gr >=3 | 0 | 0 |
| Hyperglycemia Gr 0 at Baseline to Gr >=3 | 4 | 12 |
| Hyperglycemia Gr 1 at Baseline to Gr >=3 | 13 | 13 |
| Hyperglycemia Gr 2 at Baseline to Gr >=3 | 2 | 10 |
| Hyperglycemia Gr 3 at Baseline to Gr >=3 | 3 | 2 |
| Hyperglycemia Gr 4 at Baseline to Gr >=3 | 0 | 0 |
| Hyperglycemia Gr 5 at Baseline to Gr >=3 | 0 | 0 |
NCI-CTCAE version 4.03 was used to determine Gr, where Gr refers to severity of AE: Gr 1: mild; asymptomatic/mild symptoms; Gr 2: moderate; minimal; Gr 3: severe/medically significant; Gr 4:life-threatening consequences, Gr 5:death related to AE. Abnormal values for Creatinine Clearance(Chronic kidney disease) were based on: Gr 1: estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) \<LLN-60ml/min/1.73 m\^2; Gr2: eGFR or CrCl 59-30 ml/min/1.73 m\^2; Gr3: eGFR or CrCl 29-15 ml/min/1.73 m\^2; Gr4: eGFR or CrCl \<15 ml/min/1.73 m\^2; Gr5: Death.
| Participants | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|
| Creatinine Clearance Gr 0 at Baseline to Gr >=3 | 0 |
| Creatinine Clearance Gr 1 at Baseline to Gr >=3 | 0 |
| Creatinine Clearance Gr 2 at Baseline to Gr >=3 | 0 |
| Creatinine Clearance Gr 3 at Baseline to Gr >=3 | 0 |
| Creatinine Clearance Gr 4 at Baseline to Gr >=3 | 0 |
| Creatinine Clearance Gr 5 at Baseline to Gr >=3 | 0 |
Collected over AE data was collected from the time of signed informed consent to 30 days following the last administration of study treatment (maximum duration: up to 10 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Surgery + Adjuvant Chemotherapy (SC) | 91/264 (34.5%) | 57/195 (29.2%) | 141/195 (72.3%) |
| Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) | 78/266 (29.3%) | 102/241 (42.3%) | 201/241 (83.4%) |
| Event | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/195 | 21/241 |
| Abdominal PainGastrointestinal disorders | 6/195 | 12/241 |
| EnteritisGastrointestinal disorders | 6/195 | 4/241 |
| IleusGastrointestinal disorders | 6/195 | 4/241 |
| DiarrhoeaGastrointestinal disorders | 4/195 | 5/241 |
| Mechanical IleusGastrointestinal disorders | 4/195 | 0/241 |
| PyrexiaGeneral disorders | 2/195 | 4/241 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/195 | 4/241 |
| Gastrointestinal Anastomotic LeakInjury, poisoning and procedural complications | 3/195 | 1/241 |
| EnterocolitisGastrointestinal disorders | 1/195 | 3/241 |
| Event | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 7/195 | 117/241 |
| DyspepsiaGastrointestinal disorders | 43/195 | 65/241 |
| Skin HyperpigmentationSkin and subcutaneous tissue disorders | 52/195 | 49/241 |
| Peripheral Sensory NeuropathyNervous system disorders | 8/195 | 42/241 |
| PruritusSkin and subcutaneous tissue disorders | 25/195 | 37/241 |
| MyalgiaMusculoskeletal and connective tissue disorders | 7/195 | 33/241 |
| InsomniaPsychiatric disorders | 12/195 | 30/241 |
| Lacrimation IncreasedEye disorders | 23/195 | 22/241 |
| Aspartate Aminotransferase IncreasedInvestigations | 21/195 | 20/241 |
| Alanine Aminotransferase IncreasedInvestigations | 20/195 | 18/241 |
Analysis was performed on Intent-to-Treat (ITT) population which included all randomized participants.
| Age, Continuous(years) | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) | Total |
|---|---|---|---|
| Mean | 57.28 ± 10.09 | 57.11 ± 10.03 | 57.19 ± 10.05 |
| Sex: Female, Male(Participants) | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) | Total |
|---|---|---|---|
| Female | 50 | 59 | 109 |
| Male | 214 | 207 | 421 |
| Race and Ethnicity Not Collected(Participants) | Surgery + Adjuvant Chemotherapy (SC) | Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Dec 2011 to primary completion in Jan 2019, 84 months.
Results were first posted in Mar 2020, 1 year 1 month after primary completion.
Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 84 months is above that.
Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · Oxaliplatin